Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naive advanced or metastatic esophagogastric cancer
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73583809" target="_blank" >RIV/61989592:15110/17:73583809 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00179906:_____/17:10368296 RIV/00209805:_____/17:00077874
Výsledek na webu
<a href="https://link.springer.com/content/pdf/10.1007%2Fs10120-016-0618-0.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007%2Fs10120-016-0618-0.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10120-016-0618-0" target="_blank" >10.1007/s10120-016-0618-0</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naive advanced or metastatic esophagogastric cancer
Popis výsledku v původním jazyce
This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS). Patients aged ae<yen>18 years with advanced or metastatic solid tumors were enrolled in a 3 + 3 design with S-1 dose escalation (two planned cohorts) performed according to the occurrence of dose-limiting toxicity (DLT). On day 1 of each 21-day cycle, patients received epirubicin 50 mg/m(2) followed by oxaliplatin 130 mg/m(2) (maximum 8 cycles) and then S-1 [20 mg/m(2) (cohort 1) or 25 mg/m(2) (cohort 2), twice daily]: first dose, evening of day 1; subsequent administration on days 2-14, twice daily; last dose, morning of day 15 (unlimited number of S-1 cycles). After protocol amendment, enrollment in a third cohort was restricted to patients with chemotherapy-na < ve advanced or metastatic esophagogastric cancer.
Název v anglickém jazyce
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naive advanced or metastatic esophagogastric cancer
Popis výsledku anglicky
This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS). Patients aged ae<yen>18 years with advanced or metastatic solid tumors were enrolled in a 3 + 3 design with S-1 dose escalation (two planned cohorts) performed according to the occurrence of dose-limiting toxicity (DLT). On day 1 of each 21-day cycle, patients received epirubicin 50 mg/m(2) followed by oxaliplatin 130 mg/m(2) (maximum 8 cycles) and then S-1 [20 mg/m(2) (cohort 1) or 25 mg/m(2) (cohort 2), twice daily]: first dose, evening of day 1; subsequent administration on days 2-14, twice daily; last dose, morning of day 15 (unlimited number of S-1 cycles). After protocol amendment, enrollment in a third cohort was restricted to patients with chemotherapy-na < ve advanced or metastatic esophagogastric cancer.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Gastric Cancer
ISSN
1436-3291
e-ISSN
—
Svazek periodika
20
Číslo periodika v rámci svazku
2
Stát vydavatele periodika
JP - Japonsko
Počet stran výsledku
10
Strana od-do
358-367
Kód UT WoS článku
000394981400016
EID výsledku v databázi Scopus
—